TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03136510

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban 5 mg
Description: Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban 5 mg
Description: Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month
Study: NCT03052062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipidrive
Description: LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
Study: NCT01569607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Training sessions for 5 days in a row

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study: NCT02978976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline placebo injection in the same regimen.
Study: NCT00469599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: 3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol
Description: 1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
Study: NCT01463449

Intervention type: PROCEDURE
Intervention: gastric bypass
Description: Low grade inflammation in adipose tissue before and after gastric bypass
Study: NCT04275362

Intervention type: DEVICE
Intervention: DJO Empowr PS Knee System
Description: Patients will receive a DJO Empowr PS Knee System total knee replacement

Intervention type: DEVICE
Intervention: DJO Empowr PS Knee System
Description: Patients will receive a DJO Empowr PS Knee System total knee replacement

Intervention type: DEVICE
Intervention: Stryker Triathlon Total Knee System
Description: Patients received a Stryker Triathlon Total Knee System total knee replacement

Intervention type: DEVICE
Intervention: Biomet Vanguard Complete Knee System
Description: Patients received a Biomet Vanguard Complete Knee System total knee replacement

Intervention type: DEVICE
Intervention: Control
Description: No total knee replacement

Intervention type: DEVICE
Intervention: Control
Description: No total knee replacement
Study: NCT03121053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypotone saline
Study: NCT00194428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almond enriched diet
Description: Subjects will consume 2 oz. of almond per day in addition to a low-fat diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fat caloric diet
Description: Low fat caloric diet
Study: NCT02639221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT002331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PXT002331
Study: NCT01859624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol 4 mg
Study: NCT01931566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone SR tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone placebo
Description: Pioglitazone placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone placebo
Description: Pioglitazone placebo-matching tablets
Study: NCT01929317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2mg tablet
Description: Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2mg tablet
Description: Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 8mg tablet
Description: Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 8mg tablet
Description: Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR matching Placebo tablet
Description: Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
Study: NCT03658681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saturated fat 14.9 E%
Description: Dietary cross-over study with saturated fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat 13.6 E%
Description: Dietary cross-over study with polyunsaturated fat
Study: NCT01297829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ibuprofen
Description: 800 mg IV ibuprofen 30 minutes preoperatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV normal saline
Study: NCT03294252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Folinic acid
Description: Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before PIPAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
Study: NCT04667221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Description: A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Active stimulation will be conducted with 1.5 milliampere (mA) with two electrodes using three reference electrodes for each active one for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: A high-definition tDCS set-up will be used with a battery-driven stimulator (Starstim 8, Neuroelectrics). Sham stimulation will have a 40 seconds ramp-up and down. No stimulation will be applied after this 40 seconds.
Study: NCT02565108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/Day Dose
Description: GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clobazam
Description: Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
Study: NCT03278171

Intervention type: BEHAVIORAL
Intervention: Impact Event Scale Revisited
Description: Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
Study: NCT02484885

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Xenon MRI
Description: Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
Study: NCT00973635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based education
Description: Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs.
Study: NCT00760617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2186877A
Description: Intramuscular (IM) administration, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Intramuscular (IM) administration, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Intramuscular (IM) administration, 1 dose
Study: NCT02633306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
Study: NCT02873377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Gum
Description: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Gum
Description: GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ
Description: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ
Description: GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Quitline Referral
Description: Fax referral to the State smoking Quitline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Quitline Referral
Description: Fax referral to the State smoking Quitline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Smoking Cessation Counseling
Description: One time face-to-face smoking cessation counseling and follow-up phone call
Study: NCT01773213

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ice-water-test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ice-water-test
Study: NCT01887535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 3 mg
Description: JNJ-54861911 3 mg will be administered as an oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 10 mg
Description: JNJ-54861911 10 mg will be administered as an oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 30 mg
Description: JNJ-54861911 30 mg will be administered as an oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 80 mg
Description: JNJ-54861911 80 mg will be administered as an oral suspension formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 25 mg
Description: JNJ-54861911 25 mg will be administered as a solid dose formulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as an oral suspension formulation.
Study: NCT02936596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid combination of immunosuppressive agents
Description: Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid
Study: NCT02778789

Intervention type: DRUG
Intervention: Tocilizumab
Description: Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label

Intervention type: DRUG
Intervention: Tocilizumab
Description: Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label

Intervention type: DRUG
Intervention: TNF-alpha Inhibitor
Description: Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label

Intervention type: DRUG
Intervention: TNF-alpha Inhibitor
Description: Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
Study: NCT01473901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + temozolomide
Description: The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 +temozolomide with/without radiotherapy
Description: The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
Study: NCT01147874

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: lab draws and imaging
Description: 1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
Study: NCT02099955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 IU/day or 2000 IU/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000 IU/day or 2000 IU/day for 12 weeks
Study: NCT02376153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABS deployed and active
Description: ABS is deployed onto surgical field and is turned on.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ABS deployed and NOT active
Description: ABS is deployed onto surgical field and is NOT turned on.
Study: NCT01817270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Study: NCT02615899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matched: Targeted (specific) balance exercise interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mismatched: Untargeted (non-specific) balance exercise interventions
Study: NCT02728167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-coagulation of the liver parenchyma with HIFU
Description: 6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
Study: NCT01281904

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Acupressure
Description: Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulating Acupressure
Description: Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
Study: NCT02550834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair indoors curling training
Description: 8x 90 minutes of training and playing indoors curling in 4 weeks
Study: NCT00201110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Skills
Description: Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Skills
Description: Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
Study: NCT01448980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thai Traditional Massage (TTM)
Description: Thai Traditional Massage will receive massage 2 time per week for 6 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: Physical therapy program 2 times per week for 6 weeks.
Study: NCT03008369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03561480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
Study: NCT01267500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical therapy
Description: patching or fusion exercises
Study: NCT02290769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short guide wire rapid exchange
Description: Use of short guide wire rapid exchange to guide the cannulation during primary ERCP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long guide wire
Description: Use of long wire to guide the cannulation during primary ERCP
Study: NCT02536963

Intervention type: DEVICE
Intervention: Pediatric Vision Scanning device
Description: The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.

Intervention type: OTHER
Intervention: Reference examination
Description: Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
Study: NCT04833218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Test of catecholamines level in moderate traumatic brain injury

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Test of catecholamines level in moderate traumatic brain injury
Study: NCT01070017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT-HAART
Description: For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
Study: NCT02817048

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chest tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS without chest tube placement
Description: Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS with chest tube placement